SEARCH RESULTS

6112 RESULTS

Two New p-Tau217 Blood Tests Join a Crowded Field

CONFERENCE COVERAGE 2023-12-01 Conference Coverage The blood-based p-tau marker field is getting pretty busy. In addition to existing tests by Fujirebio, Lilly, Janssen, and Meso Scale Discovery, C2N debuted a new CLIA-approved mass spectrometry-based test last August, while ALZPath In

Plasma p-Tau-217 Assays Work Well, But No Home Run for Diagnosis

CONFERENCE COVERAGE 2023-11-30 Conference Coverage Feel like your head is spinning? Like a little blood sample in a centrifuge, perhaps? No need to panic. It just means you are straining, like the rest of us, to keep up with the Alzheimer's disease plasma biomarker development fie

Can a Fatty Acid Explain Sex Differences in Parkinson’s?

RESEARCH NEWS 2023-11-28 Research News Women are less likely to get Parkinson’s disease than men, and scientists suspect this may be thanks to estrogen. But how? By binding estrogen receptor α (ERα) at synapses and rendering α-synuclein more soluble, say Silke Nuber at Brigham an

New Alzheimer’s Diagnostic Criteria Remain ‘Research Only’

CONFERENCE COVERAGE 2023-11-28 Conference Coverage The latest effort to rewrite the diagnostic criteria for Alzheimer’s disease has stirred more than a little controversy. While the proposed revisions have garnered praise from researchers for more accurately reflecting the underlying b

Do APOE4’s Lipid Shenanigans Trigger Tauopathy?

RESEARCH NEWS 2023-11-23 Research News Lipids are the hot new thing in Alzheimer’s research, with mounting evidence linking their dysregulation to amyloidosis, especially in the presence of the APOE4 allele. Now, researchers led by David Holtzman at Washington University in St. L

At the Core of Microglial Signaling: γ-Secretase

RESEARCH NEWS 2023-11-22 Research News Nestled within the plasma membrane, γ-secretase trims the ends off membrane proteins. Among its 150 known substrates, none is more famous than APP. The protease chews APPs transmembrane domain to spit out Aβ peptides that aggregate into amyl

Gauging Cognition From Your Couch? The Digital Age Has Arrived.

CONFERENCE COVERAGE 2023-11-21 Conference Coverage When COVID forced much of the world into virtual work, dementia scientists sped up their ongoing adaptation of cognitive assessments to digital versions (Dec 2021 conference news). How are they performing now? At the Clinical Trials in

Gotta Get Rid of It All: Total Plaque Clearance Key for Clinical Benefit

CONFERENCE COVERAGE 2023-11-18 Conference Coverage As researchers parse what makes amyloid immunotherapy work, one answer keeps bubbling up: Take out all plaque quickly, so that clinical benefits have time to show up. At last month’s Clinical Trials on Alzheimer’s Disease conference, h

Second-Generation γ-Secretase Modulator Heads to Phase 2

CONFERENCE COVERAGE 2023-11-17 Conference Coverage Can γ-secretase modulators stage a comeback? Scientists led by Irene Gerlach at F. Hoffmann-La Roche, Basel, Switzerland, are banking on it. At this year’s CTAD meeting, held October 24-27 in Boston, they reported that RG6289, a second

Patricidal Protein? Aβ42 said to Inhibit Its Parent, γ-Secretase

RESEARCH NEWS 2023-11-17 Research News Neuritic plaques, tau phosphorylation, microgliosis—of all the ways Aβ42 could doom the brain, few scientists might have suspected that it cripples γ-secretase, the very enzyme that creates it. Yet that is just what monomers do, according to

Unlocking Blood-Brain Barrier Boosts Immunotherapy Efficacy, Lowers ARIA

CONFERENCE COVERAGE 2023-11-11 Conference Coverage Current amyloid immunotherapies poorly enter the brain, with only one in a thousand antibodies getting through. For several years, researchers have been exploring alternate delivery methods that could allow for lower dosing and higher

After Long Wait, Aβ Oligomer Detangler Poised for Phase 2

CONFERENCE COVERAGE 2023-11-10 Conference Coverage While the trials, tribulations, and successes of Aβ immunotherapy were commanding Alzheimerologists' rapt attention, a different anti-amyloid approach has been quietly moving forward on the sidelines. PRI-002—a small molecule that

Moving Forward: RNA-Targeted Attempts at Taking Down Tau, APP

CONFERENCE COVERAGE 2023-11-09 Conference Coverage As the proteopathic drivers of Alzheimer's disease, Aβ and tau have for decades kept scientists trying to understand which of their isoforms and fragments are most to blame for the memory-robbing pathogenic cascade—and which ones

Treat Before ‘Aβ Bothers Tau,’ Scientists Say at CTAD

CONFERENCE COVERAGE 2023-11-08 Conference Coverage Some researchers have long argued for starting amyloid immunotherapy early, before tangles spread and neurons die all over the brain. At the 16th Clinical Trials on Alzheimer’s Disease conference, held October 24 to 27 in Boston and on

Current Filters

  • TYPE: News x
  • Date Range : All x

Remove all filters

Filter By

DATE RANGE
  • All
  • Past 7 Days
  • Past 30 Days
  • Past 90 Days
  • Past 12 Months
  • Specific Dates
    1. From
      To

TYPE
TYPE OF NEWS
DISEASE
TOPIC
BIOMOLECULE